Analysis of The Use of PCSK9 Inhibitors in Clinical Practice

Aim. The analysis of the experience of using PCSK9 inhibitors (alirocumab) in patients with very high cardiovascular risk, аccording to long observations in real clinical practice.

Material and methods. In study evaluated the data for 31  people (23 men and 8 women, the average  age of those surveyed was 59.4±5.8 years) of very high cardiovascular risk with atherogenic dyslipidemia  and no achievement  of the target lipid levels. Alirokumab was administered  in a dose of 150 mg subcutaneously once every 2 weeks in the day hospital of a multidisciplinary clinic. The primary endpoint was reached the target level of low density lipoprotein cholesterol (HS-LDL) level and/or reduce HS-LDL levels by 50% or more. Liver tests, level of creatinine and glycemia  were studied to assess safety; side effects studied/

Results. The long-term use of alirocumab  (on average 7,5±2,3 months) is well tolerated without adverse reactions and withdrawal syndrome, in the day hospital of a multidisciplinary clinic. 90% of patient have achieved either a target level of HS-LDL less than 1.4 mmol/l or a reduction in HS-LDL by 50% or more. The remaining  third of patients achieved both target levels. It can be distinguished a group of patients with a good response to the medication, in the first months of administration of alirokumab.

Conclusion. The results of conducting an efficiency  assessment  for use of the alirocumab  in a dose of 150 mg  subcutaneously within two weeks showed  that this therapy has the high efficacy and good tolerability without any adverse reactions,  in the day hospital of a multidisciplinary clinic.

1. Roth EM. Alirocumab for hyperlipidemia: ODYSSEY Phase III clinical trial results and US FDA approval indications. Future Cardiol. 2016 Mar;12(2):115-28. DOI:10.2217/fca.15.78.

2. Long Term Safety Study of PRALUENT [cited 2023 Jan 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT03694197.

3. An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia [cited 2023 Jan 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT03510715.

4. Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo [cited 2023 Jan 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT02957682.

5. An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (ODYSSEY KIDS) [cited 2023 Jan 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT02890992.

6. Open Label Study of Long Term Safety Evaluation of Alirocumab (ODYSSEY OLE) [cited 2023 Jan 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT01954394.

7. Chaulin AM. New groups of hypolipidemic medications based on inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9). Part 1. Clinical Medicine. 2020;98(11-12):739-44. (In Russ.) DOI:10.30629/0023-2149-2020-98-11-12-739-744

8. State register of medicines. Instructions for medical use of the drug Praluent [cited 01/10/2023]. Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=001d648b-2755-4dd3-9a85-1097927d0077 (In Russ.)

9. Chaulin A.M., Aleksandrov A.G., Aleksandrova O.S., et al. The role of the proprotein convertase subtilisin/kexin type 9 (PCSK9) in the pathophysiology of atherosclerosis. Medicine in Kuzbass. 2019;18(4):5-15 (In Russ.)

10. Table of Pharmacogenomic Biomarkers in Drug Labeling [cited 2023 Jan 10]. Available from: https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling.

11. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. DOI:10.1093/eurheartj/ehz455.

12. Baigent C, Blackwell L, Emberson J et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81. DOI:10.1016/S0140-6736(10)61350-5.

13. Wiviott SD, Cannon CP, Morrow DA, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005;46(8):1411-6. DOI:10.1016/j.jacc.2005.04.064.

14. Sabatine MS, Giugliano RP, Keech AC, et al. FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-22. DOI:10.1056/NEJMoa1615664.

15. Robinson JG, Rosenson RS, Farnier M, et al. Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab. J Am Coll Cardiol. 2017;69(5):471-82. DOI:10.1016/j.jacc.2016.11.037.